Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypaconitine is a highly toxic diterpene alkaloid derived from *Aconitum* species, most notably *Aconitum carmichaelii* (known as Fuzi in Traditional Chinese Medicine). It is one of the primary active components used for its analgesic and anti-inflammatory properties in treating conditions such as rheumatoid arthritis and joint pain. Mechanistically, hypaconitine acts as a potent activator of voltage-gated sodium channels, leading to persistent membrane depolarization, which contributes to both its therapeutic effects and its significant cardiotoxicity and neurotoxicity. The compound has a very narrow therapeutic window and is primarily metabolized by the cytochrome P450 enzyme CYP3A4 and transported by P-glycoprotein (P-gp). Due to its toxicity, plant materials containing hypaconitine are typically subjected to rigorous processing (detoxification) before medicinal use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypaconitine.